Zynex Medical Lawsuit: 2026 Updates and Payouts

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.

Zynex Medical faces multiple lawsuits heading into 2026, and if you’re an investor, patient, or former employee, you may have a claim worth pursuing. The zynex medical lawsuit saga involves securities fraud allegations, billing practice disputes, and insurance reimbursement questions that have put the Colorado-based medical device company squarely in the legal spotlight.

This article breaks down every active claim type against Zynex Medical. You’ll learn who qualifies, what the potential payouts look like, and exactly how to file.

On a related note, check out Entertainment Lawsuit East Sandra: 2026 Settlement Guide

One striking detail: Zynex’s stock price dropped more than 60% from its highs after fraud allegations surfaced, wiping out hundreds of millions in investor value. That kind of hit does not go unnoticed by the courts.

Whether you bought ZYXI stock, received a NexWave device, or worked at the company, the information below covers what you need to know right now.

Zynex Medical Lawsuit

The Zynex Medical lawsuit refers to a collection of legal actions filed against Zynex Medical Inc., a medical device company based in Lone Tree, Colorado. These cases span securities fraud, billing irregularities, and insurance reimbursement disputes.

Zynex Medical (NASDAQ: ZYXI) primarily sells electrotherapy devices, including its flagship NexWave unit. The company has faced scrutiny over how it reports revenue and how it bills insurance providers for those devices.

The earliest major lawsuit was filed in the U.S. District Court for the District of Colorado. Shareholders alleged the company made materially false statements about its financial health and business practices.

Multiple law firms filed separate but related complaints. The cases were eventually consolidated, which is common when several firms target the same defendant over similar facts.

The lawsuits paint a picture of a company that grew fast but may have cut corners on transparency. That combination tends to attract legal trouble like a magnet.

Zynex Medical Class Action Lawsuit

The Zynex Medical class action lawsuit is a consolidated securities fraud case brought on behalf of investors who purchased ZYXI stock during a specific class period. Class members argue they were misled about the company’s true financial performance.

A class action allows one or a few plaintiffs to represent thousands of people with the same grievance. In this case, the class includes anyone who bought Zynex stock during the period when false statements were allegedly being made.

The lead plaintiff, chosen by the court, represents the entire class. That person or entity typically suffered the largest financial loss among those who applied for the role.

Key facts about the class action:

• Filed in federal court in Colorado
• Alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934
• Targets both the company and individual executives, including CEO Thomas Sandgaard
• Class period covers the timeframe when allegedly misleading statements were made
• Lead plaintiff was appointed after a competitive application process

If the case succeeds, all class members share in the recovery. You don’t need to do anything to be part of the class unless you want to opt out.

This is one of the most watched medical device securities cases heading into 2026.

Zynex Medical Lawsuit Update 2026

As of early 2026, the Zynex Medical lawsuit remains active with several key developments unfolding. The case has survived motions to dismiss, which means the court found enough merit to let it proceed to discovery.

Discovery is the phase where both sides exchange evidence. This includes internal emails, financial documents, board meeting minutes, and executive communications. For plaintiffs, this is where cases often get stronger.

Settlement talks have been referenced in court filings, though no formal agreement has been announced yet. Cases of this size often settle before trial once discovery reveals the full scope of evidence.

Investors should watch for a few things this year. Any settlement announcement would trigger a claims filing process. If no settlement is reached, a trial date could be set for late 2026 or early 2027.

The company’s quarterly earnings reports may also contain relevant disclosures about litigation reserves, which can signal how seriously management views the financial exposure.

Key Takeaway: The Zynex Medical lawsuit has cleared early legal hurdles, survived dismissal attempts, and is now in the discovery phase heading into 2026, with settlement talks reportedly in motion.

Zynex Medical Securities Fraud

Zynex Medical securities fraud claims are at the heart of the shareholder litigation. Plaintiffs allege the company made false or misleading statements about its revenue, business metrics, and growth trajectory.

The core accusation is that Zynex inflated its reported revenue by recognizing income before it was actually earned. This practice, if proven, violates Generally Accepted Accounting Principles (GAAP) and misleads investors about the company’s financial health.

Specifically, plaintiffs allege:

• Revenue from device orders was booked prematurely, before insurance reimbursement was confirmed
• The company overstated the number of active prescribing physicians
• Management knew about high return and denial rates but did not disclose them
• Internal controls over financial reporting were inadequate

These allegations gained traction after short seller reports highlighted discrepancies between Zynex’s reported numbers and independent data. When those reports became public, the stock price dropped sharply.

Securities fraud cases require plaintiffs to prove that false statements were made knowingly or recklessly. They must also show that investors relied on those statements and suffered losses as a result. That standard, called “scienter,” is a high bar but not an impossible one.

The damage to shareholders was real. ZYXI stock fell from highs above $30 to single digits during the fallout period.

Zynex Medical Settlement

A Zynex Medical settlement has not been finalized as of early 2026, but signs suggest one could emerge this year. Settlement talks are common at this stage of securities litigation, especially once discovery begins revealing internal documents.

Most securities class actions settle rather than go to trial. The reason is simple: trials are expensive, unpredictable, and risky for both sides. A settlement lets the company put the matter behind it while compensating investors.

If a settlement is reached, here’s what typically happens:

• The court must approve the settlement amount and terms
• A claims administrator is appointed to handle distributions
• Class members receive notice by mail or email
• A deadline is set for filing claims (usually 60 to 120 days)
• A fairness hearing is held where objectors can speak

Comparable medical device securities settlements in recent years have ranged from $5 million to $50 million or more, depending on the size of investor losses and the strength of evidence. The final number depends heavily on what discovery reveals.

Zynex Medical Lawsuit Payout

The Zynex Medical lawsuit payout will depend on the total settlement fund, the number of eligible claimants, and the size of each investor’s losses. No payout has been distributed yet because the case has not settled.

Think of it like splitting a pie. The size of the pie (settlement fund) matters, but so does how many people are sitting at the table. More claimants means smaller individual shares.

In securities class actions, payouts are calculated using a “recognized loss” formula. This formula considers:

• When you bought shares
• How many shares you bought
• When (or if) you sold them
• The stock price at purchase versus the price after the fraud was revealed

These are rough estimates based on comparable settlements. Your actual payout could be higher or lower.

One thing to keep in mind: attorneys’ fees typically consume 25% to 33% of the settlement fund before distribution. That is standard in class actions and is approved by the court.

Key Takeaway: Individual payouts from the Zynex Medical lawsuit will vary based on your investment size and timing, with most retail investors likely receiving between $50 and $5,000 depending on the total settlement amount.

Zynex Medical Settlement Amount

The Zynex Medical settlement amount has not been determined yet, but industry benchmarks offer useful context. Securities class actions involving medical device companies of Zynex’s size typically settle in the $10 million to $40 million range.

Several factors will influence the final number:

• Total investor damages: The aggregate losses suffered by all class members during the class period
• Strength of evidence: Internal documents uncovered during discovery
• Insurance coverage: Zynex’s directors and officers (D&O) insurance policy limits
• Company’s ability to pay: Zynex’s cash position and financial health
• Risk of trial: Both sides weigh the odds of winning at trial

Companies with D&O insurance policies often settle within those policy limits. This means the settlement amount may be capped by how much insurance the executives carried, which is often between $10 million and $50 million for companies of this size.

For comparison, here are recent medical device securities settlements:

The stronger the evidence of intentional fraud, the higher the settlement tends to be. Discovery findings will be the biggest factor in pushing that number up or down.

Who Qualifies for Zynex Medical Lawsuit

You may qualify for the Zynex Medical lawsuit if you purchased ZYXI stock during the class period and suffered a financial loss. The class period is the specific timeframe when the company allegedly made misleading statements.

Qualification depends on which type of lawsuit applies to your situation. There are different eligibility criteria for investors, patients, and employees.

For investors:

• Purchased Zynex Medical common stock during the class period
• Did not sell before the stock price dropped
• Can show a net financial loss on those shares

For patients:

• Received a Zynex NexWave or TENS device
• Were billed improperly or received unexpected charges
• Had insurance claims denied due to Zynex billing practices

For employees:

• Worked at Zynex Medical
• Experienced wage violations, wrongful termination, or retaliation
• Can document the employment relationship and the adverse action

Most class action members do not need to take any action unless they want to file an individual claim or opt out. But filing a claim when the time comes is required to receive money.

Zynex Medical Lawsuit Eligibility

Zynex Medical lawsuit eligibility is determined by the type of claim and your specific connection to the company. Not everyone who interacts with Zynex qualifies for every lawsuit.

For the securities class action, eligibility is straightforward. You need to have bought stock during the class period and held it through at least some of the price decline. If you sold before any corrective disclosure, you likely won’t qualify.

Here are the key eligibility requirements broken down:

If you're curious, also see EcoShield Pest Control Lawsuit 2026: Payouts & Claims

• Securities claim: Must have purchased ZYXI shares during the defined class period. Must show a financial loss attributable to the alleged fraud.
• Billing claim: Must have been a patient who received a Zynex device. Must show evidence of improper charges or insurance denials.
• Employment claim: Must be a current or former Zynex employee with documented workplace violations.

One common question: do you need a lawyer to be eligible? The answer is no, not for class action participation. You become part of the class automatically if you meet the criteria. However, having legal representation can be helpful if you want to file a larger individual claim.

Another question that comes up: can international investors qualify? Generally yes, if you purchased shares on a U.S. exchange during the class period. Foreign exchanges are usually excluded.

Key Takeaway: Eligibility for the Zynex Medical lawsuit depends on whether you’re an investor, patient, or employee, and each category has distinct requirements for proof and timing.

Zynex Medical Billing Practices Lawsuit

The Zynex Medical billing practices lawsuit focuses on allegations that the company used aggressive or improper billing methods to generate revenue from insurance companies. These claims are separate from, but related to, the securities fraud case.

According to the allegations, Zynex’s sales model relied heavily on shipping electrotherapy devices to patients and then billing insurance for the full cost. The problem, plaintiffs argue, is that many of those insurance claims were denied or returned, but Zynex booked the revenue anyway.

The billing concerns include:

• Sending devices to patients who may not have needed them
• Billing insurance companies at inflated rates
• Not adequately verifying insurance coverage before shipping devices
• Continuing to ship devices even after high denial rates became apparent
• Failing to collect patient copays or deductibles

Patients caught in this system sometimes received unexpected bills. Others found that their insurance companies denied coverage entirely, leaving them responsible for the full cost of a device they didn’t ask for or didn’t fully understand.

These billing practices form the foundation of both the securities fraud allegations and potential state attorney general investigations.

Zynex Medical Insurance Fraud Allegations

The Zynex Medical insurance fraud allegations center on claims that the company systematically billed insurance providers for devices and services in ways that were misleading or improper. These allegations overlap with but go beyond simple billing disputes.

Insurance fraud, if proven, carries severe legal consequences. It can result in civil penalties, criminal charges, exclusion from federal healthcare programs, and treble damages under the False Claims Act.

The specific allegations include:

• Submitting claims to Medicare, Medicaid, and private insurers for devices that were not medically necessary
• Using improper billing codes to secure higher reimbursement rates
• Failing to disclose the company’s actual insurance denial rates to investors
• Pressuring sales representatives to maximize device placements regardless of medical need

These allegations drew the attention of federal regulators. The False Claims Act allows whistleblowers (called “relators”) to file qui tam lawsuits on behalf of the government. If such a case exists under seal, it would not be publicly known until unsealed.

The intersection of insurance fraud and securities fraud is what makes the Zynex situation particularly complex. Problems on the billing side directly affected the accuracy of financial statements reported to investors.

Zynex Medical SEC Investigation

Zynex Medical has faced SEC scrutiny related to its financial reporting practices. The Securities and Exchange Commission reviews companies when there are indicators of potential securities law violations, including unusual stock trading patterns and accounting irregularities.

While Zynex has not publicly confirmed an active SEC enforcement action as of early 2026, the company has disclosed in its SEC filings that it has received inquiries from regulators. These disclosures appeared in the company’s annual Form 10-K and quarterly Form 10-Q reports.

An SEC investigation can take several forms:

• Informal inquiry: The SEC requests documents and information voluntarily
• Formal investigation: The SEC issues subpoenas with legal force
• Enforcement action: The SEC files a civil complaint or administrative proceeding
• Wells Notice: A formal notification that the SEC staff intends to recommend enforcement action

If the SEC takes action, it could result in monetary penalties, disgorgement of profits, officer bars (preventing executives from serving at public companies), and mandatory corporate reforms.

SEC findings often strengthen private lawsuits. If the SEC concludes that fraud occurred, private plaintiffs can point to those findings as evidence in their own case.

Key Takeaway: SEC scrutiny of Zynex Medical’s financial reporting adds significant weight to the private securities fraud lawsuits and could lead to additional penalties beyond what shareholders recover.

Zynex Medical NexWave Lawsuit

The Zynex Medical NexWave lawsuit involves claims related to the company’s flagship electrotherapy device. The NexWave is marketed as a multiwave locked system designed to treat pain without medication, but legal claims have raised questions about how the device was sold and billed.

The NexWave is Zynex’s core product. It generates the majority of the company’s revenue. That means any problems with how NexWave is sold, prescribed, or billed have an outsized impact on the company’s financial results.

Claims related to the NexWave include:

• Devices shipped to patients without proper medical authorization
• Insurance billed for NexWave units at rates higher than comparable devices
• Patients receiving NexWave units they didn’t request or understand
• Marketing materials overstating the device’s effectiveness
• High return rates that were not disclosed to investors

The NexWave is FDA-cleared, which means it met safety and efficacy standards for its intended use. However, FDA clearance does not protect a company from fraud claims related to how the device is marketed, sold, or billed.

For patients, the concern is simple: did you receive a device you needed, at a fair price, with proper insurance authorization? If the answer to any of those questions is no, you may have a claim.

Zynex Medical Stock Lawsuit

The Zynex Medical stock lawsuit is a shareholder action focused on the dramatic decline in ZYXI share price following the disclosure of alleged fraud. Investors who bought at inflated prices and sold at lower prices after the truth came out are the primary plaintiffs.

ZYXI stock reached highs above $30 per share during the period when allegedly misleading statements were being made. After short seller reports and media coverage raised questions about the company’s practices, the stock fell below $10.

That kind of drop doesn’t just sting. For investors who put significant money into the stock based on the company’s reported growth, it felt like the rug was pulled out.

The stock lawsuit specifically targets the gap between what executives said publicly and what was actually happening inside the company. If management knew about high insurance denial rates, revenue recognition problems, or regulatory inquiries but didn’t disclose them, that’s the kind of omission that sustains a securities fraud claim.

Institutional investors, pension funds, and retail shareholders are all part of the class. The lead plaintiff is typically the investor with the largest documented loss.

Zynex Medical Employee Lawsuit

Zynex Medical employee lawsuits involve claims by current and former workers alleging workplace violations. These cases are separate from the investor-focused securities litigation and address different legal issues.

Employee claims against Zynex have reportedly included:

• Wage and hour violations: Allegations that sales representatives were misclassified or not properly compensated for overtime
• Wrongful termination: Claims by employees who say they were fired for raising concerns about company practices
• Whistleblower retaliation: Allegations that employees who reported billing irregularities faced adverse employment actions
• Hostile work environment: Claims related to management culture and working conditions

Whistleblower claims are particularly significant in the Zynex context. If employees reported billing fraud internally and were punished for it, that could provide powerful evidence for both the employment claims and the securities fraud case.

Federal law protects employees who report securities violations. Under the Dodd-Frank Act, whistleblowers can receive between 10% and 30% of any SEC monetary sanctions exceeding $1 million.

Key Takeaway: Employee lawsuits against Zynex Medical add another layer of legal exposure and may provide whistleblower evidence that strengthens the securities fraud and billing fraud cases.

How to File a Claim Against Zynex Medical

Filing a claim against Zynex Medical depends on the type of lawsuit and where the case currently stands. For the securities class action, you will need to file a proof of claim form when a settlement is approved or when the claims process opens.

Here’s a step-by-step breakdown:

Step 1: Determine your claim type
Figure out whether you’re an investor, patient, or employee. Each path has different requirements and different filing processes.

Before you go further, consider reading The Chosen Investor Lawsuit 2026: Payouts and Filing Info

Step 2: Gather your documents

• Investors: Brokerage statements showing ZYXI purchases and sales
• Patients: Billing statements, insurance denials, device records
• Employees: Pay stubs, employment records, termination letters

Step 3: Monitor for a claims notice
When a settlement is approved, the claims administrator will send notices to potential class members. Watch your mail and email.

Step 4: Complete the claim form
Fill out the form accurately. Attach supporting documents. Submit before the deadline.

Step 5: Wait for distribution
After the claims deadline passes, the administrator reviews all submissions and calculates individual payouts.

One important note: there is usually no cost to file a class action claim. You don’t pay legal fees upfront. Attorneys are paid from the settlement fund.

Zynex Medical Lawsuit Timeline

The Zynex Medical lawsuit timeline spans several years, from the initial filings to the current discovery phase. Understanding where the case stands helps you plan your next steps.

Here’s a chronological overview:

The denial of the motion to dismiss was a turning point. It meant the judge found the plaintiffs’ allegations were strong enough to warrant further proceedings. Many securities cases settle shortly after this milestone.

If the case goes to trial, expect a resolution sometime in 2027 or later. Trials in federal securities cases typically last two to four weeks.

For those waiting on money, patience is required. Even after a settlement is announced, the claims and distribution process takes an additional six to twelve months.

Is There a Class Action Against Zynex Medical

Yes, there is a class action lawsuit against Zynex Medical. The case is a securities fraud class action filed in the U.S. District Court for the District of Colorado on behalf of investors who purchased ZYXI stock during the relevant class period.

This is not a rumor or a potential case. It’s an active, consolidated legal proceeding with an appointed lead plaintiff, experienced class action attorneys, and a federal judge overseeing the matter.

Key facts about the class action:

• Case type: Securities fraud (Sections 10(b) and 20(a) of the Exchange Act)
• Court: U.S. District Court, District of Colorado
• Defendants: Zynex Medical Inc., Thomas Sandgaard, and other officers
• Class: All investors who purchased ZYXI common stock during the class period
• Status: Active, in discovery phase as of 2026
• Law firms involved: Multiple firms specializing in securities litigation

You don’t need to sign up to be part of the class. If you qualify, you’re included unless you choose to opt out. When the time comes to file a claim or receive a payout, you’ll be notified.

Key Takeaway: A confirmed securities fraud class action against Zynex Medical is active in federal court, and anyone who purchased ZYXI stock during the class period is automatically a member unless they opt out.

Frequently Asked Questions

How much money can I get from the Zynex Medical lawsuit?

Most retail investors can expect between $50 and $5,000, depending on the total settlement fund and the size of your investment.

Your exact payout depends on when you bought shares, how many you held, and when you sold.

Distributions are not expected until a settlement is finalized, likely in late 2026 or 2027.

Who qualifies to join the Zynex Medical class action?

Anyone who purchased ZYXI stock during the court-defined class period qualifies automatically.

You don’t need to sign up or hire a lawyer to be included.

Patients who were improperly billed and employees with workplace claims may have separate legal options.

What is the deadline to file a Zynex Medical lawsuit claim?

No claims filing deadline has been set yet because a settlement has not been finalized.

Once a settlement is approved, class members will typically have 60 to 120 days to submit claims.

Watch for official notice by mail or email from the appointed claims administrator.

Is Zynex Medical under SEC investigation?

Zynex Medical has disclosed receiving regulatory inquiries in its SEC filings.

No formal enforcement action has been publicly announced as of early 2026.

SEC investigations can remain confidential for years before any public action is taken.

What are the main allegations in the Zynex Medical lawsuit?

The primary allegations are securities fraud, including premature revenue recognition, inflated business metrics, and failure to disclose high insurance denial rates.

Billing practice claims allege the company submitted improper insurance claims for its NexWave devices.

Employee lawsuits have raised additional concerns about whistleblower retaliation and wage violations.

What to Do Next

The Zynex Medical lawsuit is heading toward a resolution point in 2026. If you qualify as an investor, patient, or employee, now is the time to gather your documents and stay alert for claim notices.

Don’t wait for a settlement announcement to get organized. Pull your brokerage statements, billing records, or employment files now.

When the claims process opens, acting fast and filing accurately will give you the best chance at maximum recovery. Keep an eye on court filings and news updates throughout 2026.

You may want to read Developing Golf Lawsuit 2026: Settlements and Filing Guide

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.